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Abstract
Background: Cellulose acetate phthalate (CAP) in soluble form blocks coreceptor binding sites
on the virus envelope glycoprotein gp120 and elicits gp41 six-helix bundle formation, processes
involved in virus inactivation. CAP is not soluble at pH < 5.5, normal for microbicide target sites.
Therefore, the interaction between insoluble micronized CAP and HIV-1 was studied. Carbomer
974P/BufferGel; carrageenan; cellulose sulfate; dextran/dextrin sulfate, poly(napthalene sulfonate)
and poly(styrene-4-sulfonate) are also being considered as anti-HIV-1 microbicides, and their
antiviral properties were compared with those of CAP.
Methods: Enzyme linked immunosorbent assays (ELISA) were used to (1) study HIV-1 IIIB and BaL
binding to micronized CAP; (2) detect virus disintegration; and (3) measure gp41 six-helix bundle
formation. Cells containing integrated HIV-1 LTR linked to the β-gal gene and expressing CD4 and
coreceptors CXCR4 or CCR5 were used to measure virus infectivity.
Results:  1) HIV-1 IIIB and BaL, respectively, effectively bound to m i c r o n i z e d  C A P .  2 )  T h e
interaction between HIV-1 and micronized CAP led to: (a) gp41 six-helix bundle formation; (b)
virus disintegration and shedding of envelope glycoproteins; and (c) rapid loss of infectivity.
Polymers other than CAP, except Carbomer 974P, elicited gp41 six-helix bundle formation in HIV-
1 IIIB but only poly(napthalene sulfonate), in addition to CAP, had this effect on HIV-1 BaL. These
polymers differed with respect to their virucidal activities, the differences being more pronounced
for HIV-1 BaL.
Conclusions: Micronized CAP is the only candidate topical microbicide with the capacity to
remove rapidly by adsorption from physiological fluids HIV-1 of both the X4 and R5 biotypes and
is likely to prevent virus contact with target cells. The interaction between micronized CAP and
HIV-1 leads to rapid virus inactivation. Among other anionic polymers, cellulose sulfate, BufferGel
and aryl sulfonates appear most effective in this respect.
Background
Several anionic polymers were shown to have HIV-1 in-
hibitory activity and are being considered and evaluated
as vaginal topical microbicides for prevention of transmis-
sion of sexually transmitted disease (STD) pathogens, in-
cluding HIV-1. These polymers belong to several classes:
(1) sulfate esters of polysaccharides (dextrin and dextran
sulfates [1–11]; cellulose sulfate [12–15]; sulfate esters of
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galactose + 3,6-anhydrogalactose copolymers {carrageen-
an; [1,16–19]}); (2) polymers containing sulfonated ben-
zene or naphthalene rings {poly(styrene-4-sulfonate)
[20,21]} and naphthalene sulfonate polymers {PRO2000
[22–24]}; and (3) polycarboxylates (acrylic acid polymers
{Carbomer 974P; BufferGel [25–29]}); and acetyl
phthaloyl cellulose {cellulose acetate phthalate (CAP)
[30–37]}.
The mechanisms involved in sexual transmission of HIV-
1 appear to be complex and are not yet fully defined
[38,39]. Thus, a microbicide with HIV-1 inhibitory activi-
ty could provide protection in vivo only if both the com-
pound and the virus reach susceptible cells before
productive infection could occur. This might be difficult
to accomplish. For this reason, it is preferable that micro-
bicides irreversibly inactivate the virus upon the first com-
pound/HIV-1 encounter in the vaginal environment, i.e.
microbicides should have direct virucidal activity. Such
activity was reported for dextran sulfate after 2 h incuba-
tion with HIV-1 [2] but results of other studies indicated
that dextran sulfate failed to neutralize virus infectivity
[4,10]. Inactivation of HIV-1 by carrageenan was reported
in a review article [18]. BufferGel is virucidal against HIV-
1 by providing a buffered low pH environment (pH 3.9
[25]), but virus inactivation might be incomplete and pos-
sibly compromised by minor pH increases due to the pres-
ence of seminal fluid [40]. To be effective in preventing
infection by direct virus inactivation, anti-HIV-1 microbi-
cides must be virucidal against both X4 and R5 viruses,
utilizing CXCR4 and CCR5 as coreceptors [39,41], respec-
tively, R5 HIV-1 being most frequently sexually transmit-
ted. Recent results [36,37], (R. Shattock, personal
communication) indicate that CAP in soluble form meets
these requirements. Since CAP, unlike the other polymers
listed above, is not soluble at low pH, characteristic for a
normal vaginal environment [42], micronized forms of
CAP had to be used in microbicidal formulations of this
compound [30–34]. Therefore, it was of interest to deter-
mine how CAP in micronized form and other candidate
polymeric microbicides affect X4 and R5 viruses repre-
sented by HIV-1 IIIB and BaL, respectively.
Methods
Reagents
Aquateric (the micronized form of CAP containing 
66% CAP and  34% of Poloxamer and distilled acetylat-
ed monoglycerides) was obtained from the FMC Corpora-
tion, Philadelphia, PA. Cellulose acetate phthalate (CAP)
was a gift from Eastman Chemical Company, Kingsport,
TN, and micronized using a SPEX 6800 freezer mill (SPEX
CertiPrep, Metuchen, NJ) with the following settings: pre-
cooling time 10 min, cooling time 1 min, input frequency
15; 3 cycles of 3 min each. The following additional poly-
mers were obtained from commercial sources likely to be
different from those for proprietary products being devel-
oped as microbicides: carrageenans κ and λ (Sigma, St.
Louis, MO; mixed at a 1:1 (w/w) ratio in all experiments);
cellulose sulfate (Across Organics, Piscataway, NJ); dex-
tran sulfate (M.W. 500,000; Pharmacia, Kalamazoo, MI);
poly(naphthalene sulfonate) (BASF, Parsippany, NJ); po-
ly(styrene-4-sulfonate) (Polysciences, Inc., Warrington,
PA); and Carbomer 974P (B. F. Goodrich, Cleveland,
OH). Poloxamer {an α-Hydro-γ-hydroxypoly(oxyethyl-
ene)poly(oxypropylene)poly(oxyethylene) block copoly-
mer} was from Spectrum, New Brunswick, NJ. Goat
serum was from Atlanta Biologicals, Norcross, CA. Buffer-
Gel was a gift from Dr. Kevin J. Whaley, John Hopkins
University. The mouse monoclonal antibody (mAb), NC-
1, raised against the gp41 six/helix bundle from HIV-1 IIIB
was prepared as described [43] and shown to react also
with six-helix bundles from HIV-1 BaL [37]. Rabbit anti-
bodies against the gp41 six-helix bundle and against HIV-
1 IIIB gp120 were prepared as described [44,45]. The latter
antibodies were shown to crossreact with HIV-1 BaL
gp120 [37]. Rabbit antibodies against HIV-1 tat as well as
recombinant HIV-1 IIIB gp120 and biotinylated soluble
CD4 (sCD4) were from ImmunoDiagnostics, Inc.,
Woburn, MA. Horseradish peroxidase (HRP) labeled
streptavidin was from Zymed, South San Francisco, CA.
HRP labeled goat anti-rabbit IgG was from Southern Bio-
technology Associates, Inc., Birmingham, AL. HRP was
quantitated using a kit from Kirkegaard & Perry Laborato-
ries, Inc., Gaithersburg, MD. Biotin labeled mouse IgG
was obtained from the Roche Diagnostics Corporation,
Indianapolis, IN. Recombinant protein A/G was from
Pierce, Rockford, IL. Enzyme linked immunosorbent as-
say (ELISA) kits for the HIV-1 p24 antigen were from
Beckman Coulter, Inc., Miami, FL. Pelletted, 1000-fold
concentrates of HIV-1 IIIB (6.8 × 1010 virus particles/ml)
and BaL (2.47 × 1010 virus particles/ml) [46] were from
Advanced Biotechnologies, Inc., Colombia, MD. Human
seminal fluid was purchased from New England Immu-
nology Associates, Cambridge, MA. HeLa-CD4-LTR-β-gal
and MAGI-CCR5 cells were obtained from the AIDS Re-
search and Reference Reagent Program contributed by
Drs. M. Emerman and J. Overbaugh. Dulbecco's modified
Eagle medium (DMEM) was from GIBCO™ Invitrogen
Corporation, Carlsbad, CA. The Galacto-Light Plus chemi-
luminescence reporter assay for β-galactosidase was from
Applied Biosystems, Foster City, CA.
Citrate/phosphate buffers in the pH range of 2.9 – 5.0
were prepared as described [47].
Enzyme-linked immunosorbent assays (ELISA)
The sandwich ELISA for gp41 six-helix bundles was per-
formed as described [37,45]. HIV-1 IIIB and BaL virus
preparations, respectively, treated with distinct anionic
polymers, were precipitated with 3% polyethylene glycolBMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/27
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6000 (PEG) in order to separate virus particles from excess
compounds. The pellets were dissolved in lysis buffer [1%
Nonidet P40 {NP40}, 100 µg/ml bovine serum albumin
(BSA) in phosphate buffered saline (PBS)], incubated for
30 min at 20°C and then added to wells coated with rabbit
polyclonal antibodies to the gp41 core. Control virus was
treated similarly. The lysis buffer was used as a safety pre-
caution to minimize work with potentially infectious vi-
rus. Similar results were obtained when PBS was used for
resuspension of virus particles instead of lysis buffer. After
incubation at 4°C overnight, the bound six-helix bundles
were detected by adding mAb NC-1 (1 µg/ml in PBS/1%
BSA/1% gelatin {100 µl/well} for 1 h at 37°C. Subse-
quently the wells were washed three times with PBS/
0.05% Tween 20, and biotin labeled anti-mouse IgG (100
µl/well; 125 ng/ml diluted in PBS containing 1% dry fat-
free milk) was added. After incubation for 1 h at 37°C the
wells were washed and HRP-streptavidin (125 ng/ml in
PBS containing 10% goat serum; 100 µl/well) was added.
After incubation for 1 h at 37°C, the wells were washed six
times with PBS/0.05% Tween 20. Bound HRP was detect-
ed using the test kit from Kirkegaard & Perry Laboratories
following the manufacturer's protocol, and the absorb-
ance was read at 450 nm.
Recombinant gp120 HIV-1 IIIB in the presence of a 10-
fold excess of BSA and gelatin, respectively, was quantitat-
ed by adding the gp120/BSA/gelatin mixtures (before and
after binding to micronized CAP or Aquateric; Fig. 1) at se-
rial 5-fold dilutions (2-fold to 3.9 × 106-fold in 0.14 M
NaCl-0.01 M Tris {TS}) to 96-well polystyrene plates (Im-
mulon II, Dynatech Laboratories, Inc. Chantilly, VA). Af-
ter overnight incubation at 4°C, the wells were washed
and rabbit anti-gp120 (diluted 1:1,000 in 20% goat serum
– 0.05% Tween 20 in PBS pH 7.4) was added. After 2 h at
37°C the wells were washed and HRP labeled goat anti-
rabbit IgG (diluted in 1% BSA – 0.25% gelatin – 0.05%
Tween 20 in PBS pH 7.4; {250 ng/well}) was added. After
2 h at 37°C bound HRP was detected using the kit from
Kirkegaard & Perry Laboratories. The quantity of gp120
not adsorbed to CAP/Aquateric was determined from cal-
ibration curves relating absorbance readings to the con-
centration of gp120 not exposed to CAP/Aquateric.
The envelope glycoprotein gp120 released from HIV-1
BaL was quantitated as follows: Wells of polystyrene
plates were first coated with protein A/G (1 µg/well) in 0.1
M Tris buffer, pH 8.8 for 2 h at 20°C followed by polyclo-
nal rabbit anti-gp120 (diluted 500-fold) for 1 h at 20°C.
Serial 2-fold dilutions in PBS containing 1% BSA and 1%
gelatin (PBS-BG) of preparations containing gp120 were
added to the wells. After 4 h at 20°C the wells were washed
and bound gp120 was detected by addition of biotinyl
sCD4 (1 µg) followed by HRP streptavidin. Bound HRP
was quantitated as described above. The experiments were
done in triplicate.
Measurements of HIV-1 infectivity
Two-fold serial dilutions of HIV-1 IIIB treated with dis-
tinct anionic polymers, and separated from these poly-
mers by precipitation with 3% PEG or by centrifugation at
14,000 rpm for 1 h, and control virus (100 µl), respective-
ly, were added to HeLa-CD4-LTR-β-gal cells which had
been plated a day before infection in 96-well plates at 1 ×
104 cells/well in 100 µl of DMEM medium containing
10% fetal bovine serum (FBS). In some experiments, anti-
HIV-1 tat IgG (25 µg) was added to treated and control vi-
rus to suppress the effect of extracellular tat, which may
have been present in the virus preparations, on virus infec-
tion [48,49]. After incubation at 37°C for 48 h, the culture
supernatant fluids were removed and the cells washed
once with PBS. Subsequently, 50 µl of lysis buffer from the
Galacto-Light Plus kit were added to the wells for 1 h at
20°C. Aliquots (20 µl) of the cell lysates were transferred
into wells of 96-well microplates and β-galactosidase was
quantitated using the Galacto-Light Plus System chemilu-
minescence reporter assay in a Microlight ML 2250 lumi-
nometer (Dynatech Laboratories, Inc. Chantilly, VA). The
infectivity of treated and control HIV-1 BaL was measured
Figure 1
Binding of HIV-1 IIIB gp120 to micronized CAP and Aqua-
teric, respectively. Graded quantities of micronized CAP and
Aquateric, respectively, in 0.5 ml of 0.14 M NaCl were mixed
with 100 µl of a solution containing 1 µg of HIV-1 IIIB gp120,
and 10 µg each of bovine serum albumin (BSA) and gelatin.
After incubation for 5 min at 37°C the mixtures were cooled
on ice, centrifuged at 10,000 rpm and the supernatant fluids
were filtered through 0.45 µ filters which had been pre-
washed with a solution containing 100 µg/ml of each BSA and
gelatin in 0.14 M NaCl. gp120 in the filtrates was determined
as described in the Methods section. The percentage of
gp120 recovered in the filtrates was determined from cali-
bration curves relating absorbance readings to the concen-
tration of gp120.
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by the same method except that MAGI-CCR5 cells were
used.
Measurement of HIV-1 infectivity in seminal fluid is im-
peded by the cytotoxicity of seminal plasma [50,51]. con-
tributed to by spermine [52]. Such effects were minimized
by using for titrations of virus infectivity pellets after pre-
cipitation with 3% PEG or after centrifugation (14,000
rpm for 1 h).
Results
Micronized CAP induces gp41 six-helix bundle formation 
and is virucidal against HIV-1
Earlier studies [36,37]. indicated that soluble CAP at neu-
tral pH binds to the CXCR4 and CCR5 coreceptor binding
sites on HIV-1 IIIB and BaL, respectively, and induced the
formation of "dead-end" gp41 six-helix bundles. These
two properties of soluble CAP appear to be involved in the
virus inhibitory and virucidal activities of this compound.
However, CAP is not soluble at < pH 5.5 and would pre-
cipitate in a healthy human vaginal environment which is
mildly acidic with a pH range of 3.5 – 4.5 [53]. The pre-
cipitate would have drastically reduced antiviral activity.
To overcome this problem, CAP in a micronized form was
used and proven to have virucidal activity against HIV-1
IIIB [31] and shown to be effective in reducing vaginal in-
fection by simian immunodeficiency virus (SIV) in a
macaque model [34]. Micronized CAP provides a low pH
buffering system and this may have contributed to its viru-
cidal properties. In order to correlate the properties of
CAP in soluble and micronized forms, it was necessary to
establish whether or not micronized CAP would bind
HIV-1 virus particles and HIV-1 envelope glycoproteins,
and induce the formation of gp41 six-helix bundles, a
marker of irreversible virus inactivation, as did soluble
CAP [37]. First it was established that HIV-1 gp120 bound
to micronized CAP (provided in the form of micronized
CAP particles or of a commercial product, "Aquateric",
containing about 66% of CAP and used for enteric coating
of tablets and capsules in the pharmaceutical industry
[54]); (Fig. 1). Similar results were obtained when gp120
was diluted in seminal fluid (diluted 1:1 with 0.14 M Na-
Cl). Under these conditions, ≥ 99.9997% of gp120 bound
to micronized CAP and Aquateric (final concentration of
CAP: 121.5 mg/ml), respectively. HIV-1 IIIB and BaL virus
particles also bound effectively in the presence of seminal
fluid to Aquateric formulated into a topical gel (Fig. 2).
As a result of interaction with micronized CAP (in the
form of Aquateric), the integrity of both HIV-1 IIIB and
HIV-1 BaL virus particles was strikingly affected as indicat-
ed by the observation that most of the p24 antigen after
virus contact with micronized CAP was no longer precipi-
table by 3% polyethylene glycol 6000 (PEG) unlike p24
antigen within untreated virus particles which precipitates
under these conditions (Fig. 3). Furthermore, interaction
with micronized CAP elicited the formation of gp41 six-
helix bundles which were undetectable or present at low
levels in untreated virus particles [37]. The six-helix bun-
dles detectable by ELISA were mostly not precipitable by
3% PEG indicating that they were no longer associated
with virus particles (Fig. 3). Furthermore, they were de-
tected partially (HIV-1 IIIB) or entirely (HIV-1 BaL) in a
form not bound anymore to the micronized CAP parti-
cles, unlike most of the virus-derived p24 antigen. This
suggests that interaction of virus particles with micronized
CAP resulted in stripping off of the viral envelopes which
was more noticeable with HIV-1 BaL than with HIV-1 IIIB.
To confirm that gp41 six helix bundle formation was
caused by contact of virus particles with the micronized
form of CAP (= Aquateric) and not by low pH contributed
by CAP, purified HIV-1 III B and BaL, respectively, was ex-
posed for 5 min at 37°C to acidic buffers (final pH 2.9,
3.5, 4.0, 4.5 and 5.0). The suspensions were neutralized
Figure 2
Binding of HIV-1 IIIB and BaL, respectively, to Aquateric in
the presence of human seminal fluid. Five hundred µl aliquots
of a formulation containing Aquateric (18% Aquateric, 6%
hydroxypropyl methylcellulose, 76% glycerol) were mixed
with graded volumes of seminal fluid (range: 100 µl – 1,000
µl) each containing equal amounts of purified HIV-1 IIIB (6.8
× 109 particles) and BaL (2.5 × 109 particles), respectively.
After incubation for 5 min at 37°C the mixtures were cooled
in ice, centrifuged at 10,000 rpm for 10 min in order to pellet
Aquateric. The supernatant fluids were all adjusted to identi-
cal volumes (1.5 ml) and NP40 was added to a final concen-
tration of 1%. After incubation for 30 min at 37°C, serial 5-
fold dilutions (1/1,000 to 1/3.9 × 108) were prepared and p24
antigen in each dilution was measured by ELISA. The per-
centage of p24 antigen (representing a relative measure of
the number of HIV-1 virus particles) was determined from
calibration curves relating absorbance readings to the con-
centration of p24 antigen.
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and assayed by ELISA for six-helix bundles. The results
were negative (absorbance in the 0 to 0.068 range, the
same as for viruses exposed to pH 7.0 in the absence of
CAP). Poloxamer, a constituent of Aquateric (≤ 33%) at a
final concentration of 30 mg/ml also did not induce the
formation of six-helix bundles.
Results shown above indicated that HIV-1 adsorbed onto
micronized CAP and that the CAP – virus interaction lead
to the formation of gp41 six-helix bundles, a hallmark for
HIV-1 inactivation. [37] To confirm that contact of virus
with micronized CAP leads to loss of HIV-1 infectivity,
HIV-1 IIIB and BaL, respectively, were diluted in seminal
fluid and the diluted virus preparations were mixed with
an Aquateric formulation (for composition, see legend to
Fig. 2) at volume ratios of 3:1, 1:1 and 1:3 for 5 min at
37°C. Subsequently, the micronized Aquateric particles
were sedimented by centrifugation. The supernatant flu-
ids were brought to pH 7.0 and the pellets were dissolved
by addition of Na3PO4 (final pH = 7.0). All fractions were
then precipitated by 3% PEG and the redissolved pellets
tested at 2- to 256-fold dilutions for infectivity (see Meth-
ods section). Infectious virus was undetectable (≥ 99.6%
and ≥ 99.2% inactivation of HIV-1 IIIB and BaL, respec-
tively). Similar results were obtained with other CAP for-
mulations (data not shown).
Induction of six-helix bundle formation by polymeric ani-
onic candidate microbicides
Since elicitation of gp41 six-helix bundles might be in-
volved in, or contribute to the virucidal activity of candi-
date microbicides, it was of interest to determine whether
anionic polymers other than CAP also induced six-helix
bundle formation in HIV-1 IIIB and BaL virus particles.
Results in Fig. 4 show that carrageenan, cellulose sulfate,
dextran sulfate, poly(napthalene sulfonate) and poly(sty-
rene-4-sulfonate) all elicit gp41 six-helix bundle forma-
tion in HIV-1 IIIB but somewhat less effectively in
comparison with CAP. On the other hand, Carbomer
974P, the active ingredient in BufferGel, was inactive in
this respect. Strikingly different results were obtained for
HIV-1 BaL (Fig. 5), and show that only CAP and to a lesser
extent poly(napthalene sulfonate) elicited gp41 six-helix
bundles detectable by ELISA.
Effect of anionic polymeric microbicide candidates on the 
integrity of HIV-1 particles
Since micronized CAP caused the dissociation of HIV-1
particles [31]; (Fig. 3), it was of interest to determine
whether anionic polymeric candidate microbicides in sol-
uble form at neutral pH would have similar effects. While
no such effects were seen with HIV-1 IIIB, the integrity of
HIV-1 BaL appeared to be partially diminished by treat-
ment with CAP and drastically affected by cellulose sulfate
(Fig. 6). The latter finding was confirmed by the observa-
tion that HIV-1 BaL gp120 was no longer precipitable by
3% PEG or pellettable by centrifugation after treatment of
the virus with cellulose sulfate, unlike gp120 associated
with untreated virus particles (Fig. 7). This was not seen
with cellulose sulfate treated HIV-1 IIIB (data not shown).
Comparative virucidal activity of polymeric anionic micro-
bicide candidates
HIV-1 IIIB and BaL, respectively, were treated with the dis-
tinct polymers (10 mg/ml) for 5 min at 37°C and the in-
fectivity of the treated viruses was compared with that of
control untreated HIV-1. In repeated experiments with
HIV-1 IIIB, soluble and micronized CAP, cellulose sulfate,
poly(naphthalene sulfonate), poly(styrene-4-sulfonate)
and BufferGel, respectively, caused a ≥ 140-fold reduction
in infectivity, while dextran sulfate, carrageenan and Car-
bomer 974P (pH 7), respectively, were less effective (4- to
Figure 3
Aquateric causes the disintegration of HIV-1 IIIB and BaL
virus particles and induces the formation of gp41 six-helix
bundles. Equal volumes of HIV-1 IIIB and BaL virus prepara-
tions (6.8 × 1010 and 2.47 × 1010 virus particles, respectively,
per ml) and the Aquateric formulation (see legend to Fig. 2)
were mixed and incubated for 5 min at 37°C. Aquateric was
pelletted by centrifugation at 10,000 rpm for 10 min and the
supernatant fluids were neutralized by addition of 1 M
Na2HPO4and filtered through 0.45 µ filters. The pellets con-
taining Aquateric and adsorbed virus antigens were resus-
pended and brought to pH 7.0 by addition of 1 M Na3HPO4.
The supernatant fluids and the resuspended pellets, respec-
tively, were mixed with a solution of PEG 6000 (final concen-
tration 3%). The supernatant fluids and the resuspended
pellets after PEG precipitation were mixed with NP40 (final
concentration 1%). After incubation for 30 min at 37°C and
20°C, respectively, p24 antigen and six-helix bundles in the
supernatant fluids and resuspended pellets were measured by
ELISA.
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25-fold reduction in infectivity). A typical example for
HIV-1 IIIB is shown in Fig. 8.
Representative results shown in Fig. 9 indicate that the
polymers differed from each other more substantially
with respect to their capacity to inactivate HIV-1 BaL, mi-
cronized CAP, cellulose sulfate, BufferGel and the aryl sul-
fonates being most effective.
Inhibitory effect of polymeric anionic microbicide candi-
dates on blood clotting
For the selection of the most promising candidate micro-
bicides, it is important to compare not only their virus in-
hibitory and virucidal activities, but to also study their
potential untoward effects. Since heparin and other ani-
onic polymers are known to inhibit blood clotting [55],
the effect of anionic polymeric microbicide candidates on
blood clotting was measured. While CAP, carrageenan
and BufferGel (Carbomer 974P) had moderate or no ef-
fects, cellulose sulfate, dextran sulfate, poly(napthalene
sulfonate) and poly(styrene-4-sulfonate) greatly inhibited
clotting of ACD plasma (Fig. 10). The increase in clotting
time might be potentially undesirable for topical applica-
tions under conditions of local preexisting injury or bleed-
ing.
Discussion
Several anionic polymers are being considered as topical
microbicides to prevent sexual transmission of HIV-1.
They include: (1) sulfate esters of polysaccharides {carra-
geenan [1,16–19], cellulose sulfate [12–15], and dextran
or dextrin sulfate [1–11]}; (2) aryl sulfonates {poly(naph-
thalene sulfonate) [22–24] and poly(styrene-4-sulfonate)
[20,21]}; and (3) aliphatic {Carbomer 974P/BufferGel
[25–29]} and aromatic carboxylates {CAP [30–37]}. The
anti-HIV-1 properties of these polymers are expected to
depend on their complexation with virus proteins which
is likely to occur mainly through the formation of salt
linkages or ion pairs between oppositely charged groups
on the polymers and virus proteins, respectively [56].
However, the anti-HIV-1 properties of these polymers
may depend not only on their charge density, but also on
the characteristics of their uncharged portions, which may
be involved in hydrophobic and hydrogen bonding inter-
actions which can elicit profound conformational chang-
es in hydrophobic regions of proteins and cause
disassembly of complex proteins consisting of subunits
[57]. For these reasons it is not be expected that all anionic
Figure 4
gp41 six-helix bundle induction in HIV-1 IIIB by distinct ani-
onic polymers representing candidate microbicides. Purified
HIV-1 IIIB (7 × 109 particles in TS) was precipitated with 3%
PEG. The pellets were resuspended in 100 µl of phosphate
buffer saline (PBS) to separate the virus from soluble HIV-1
antigens in the preparation. The different anionic polymers
(listed on the ordinate) were added to a final concentration
of 5 mg/ml except for Carbomer 974P (2.5 mg/ml). After
incubation for 5 min at 37°C, the mixtures were cooled in
ice and PEG was added (final concentration 3%). The pellets
after centrifugation were washed once with 3% PEG in PBS,
repelletted and finally resuspended in PBS containing 1%
NP40 and 100 µg/ml BSA and incubated at 20°C for 30 min.
The formation of six-helix bundles was determined by ELISA
(see Methods section). All experiments were done in tripli-
cate, the absorbance readings are shown as percentages of
the absorbance corresponding to six-helix bundles elicited by
CAP (= 100%).
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gp41 six-helix bundle induction in HIV-1 BaL by distinct ani-
onic polymers respresenting candidate microbicides. Purified
HIV-1 BaL (2.5 × 109 particles in Dulbecco's modified Eagle
medium {DMEM} + 20% fetal bovine serum {FBS}) were pre-
cipitated with 3% PEG and subsequently treated as described
in the legend for Fig. 4.
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polymers, considered as anti-HIV-1 microbicides, would
have similar biological activities.
In vivo protection by anti-HIV-1 compounds against sexu-
al transmission of the virus could only be accomplished if
the compounds at sufficient concentrations, and the virus
both reach susceptible cells within genital mucosa before
productive infection could occur [38,39]. Considering the
complex events involved in sexual transmission of HIV-1,
this might not be easily accomplished. Therefore, inactiva-
tion of HIV-1 infectivity preceding virus contact with sus-
ceptible target cells should be considered a preferred
mechanism of protection against infection. For this rea-
son it was of interest to study the virucidal activity of ani-
onic polymeric microbicide candidates against both X4
(using CXCR4 as coreceptor) and R5 (using CCR5 as core-
ceptor) viruses, the latter being most frequently transmit-
ted sexually [39].
Soluble CAP at neutral pH was shown to bind strongly to
the coreceptor binding sites on gp120 of both X4 and R5
viruses [36] and to elicit the formation of gp41 six-helix
bundles, the hallmark of irreversible virus inactivation
[37]. Thus, HIV-1 exposed to CAP at sufficient concentra-
tions is rendered noninfectious, and continued presence
of CAP is not required to maintain lack of infectivity. CAP
differs from all other anionic polymers listed above, in
that it is not soluble at pH < 5.5. Therefore, CAP would be
expected to precipitate in a normal acidic vaginal environ-
ment. To avoid this, CAP in micronized form (which does
not aggregate at low pH), instead of CAP in soluble form
is being considered as a topical microbicide [30–35]. Mi-
cronized CAP (Aquateric) was shown to be virucidal
against HIV-1, herpesviruses and several nonviral sexually
transmitted disease (STD) pathogens [30–34]. The viru-
cidal activity of micronized CAP could at least partly be
explained by its buffering capacity at low pH [40] since it
is a free acid while other anionic polymeric microbicide
candidates (except BufferGel, the active ingredient of
which is Carbomer 974P [27]) are sodium salts. Results
presented here explain how micronized CAP inactivates
HIV-1. Both the envelope glycoprotein gp120 (Fig. 1) and
HIV-1 IIIB and BaL virus particles (Fig. 2) in the presence
of an excess of nonviral proteins, including seminal fluid,
bind effectively to micronized CAP. Under in vivo condi-
tions (when the virus concentrations are by one to four or-
ders of magnitude lower than those used here under
experimental conditions [58,59], (Fig. 2)), this would be
expected to physically remove virus particles by adsorp-
tion onto micronized CAP (Aquateric) so that they would
cease to be available to initiate the complex sequence of
events leading to mucosal infection. Furthermore, interac-
Figure 6
Effect of anionic polymeric microbicide candidates on the
integrity of HIV-1 IIIB and BaL virus particles. Purified HIV-1
IIIB (7 × 109 particles/100 µl) and BaL (2.5 × 109 particles/100
µl) untreated or treated with the polymeric substances
shown on the abscissa (final concentrations 5 mg/ml except
for Carbomer 974P {2.5 mg/ml}) for 5 min at 37°C. The mix-
tures were cooled on ice and the virus particles were pellet-
ted by centrifugation (1 h at 14,000 rpm in a Beckman 5415
C microfuge). The pellets were resuspended in lysis buffer
(1% NP40, 100 µg/ml BSA in PBS) and incubated for 30 min
at 37°C. p24 antigen was determined in serial dilutions of the
lysates by ELISA. The levels of p24 antigen in the treated
virus preparations were compared with those corresponding
to lysed untreated virus (= 100%).
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SOLUBLE CAP (pH 7)
CELLULOSE SULFATE
UNTREATED
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Figure 7
Release of gp120 from HIV-1 BaL by treatment with cellulose
sulfate. Purified HIV-1 BaL (2.5 × 109 particles/100 µl) was
treated with cellulose sulfate (final concentration 5 mg/ml)
for 5 min at 37°C. The mixture was cooled in ice and divided
into 2 aliquots. One aliquot was centrifuged for 1 h at 14,000
rpm and the 2nd aliquot was precipitated with PEG 6000
(final concentration 3%). gp120 in the respective supernatant
fluids and pellets (resuspended in PBS) was determined by
ELISA as described [37]; (see Methods section).
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tion with micronized CAP elicits the formation of gp41
six-helix bundles and causes the stripping off of HIV-1 en-
velope glycoproteins (Fig. 3). The formation of gp41 six-
helix bundles was not due to exposure to a low pH envi-
ronment provided by the micronized CAP, since exposure
to low pH buffers did not elicit gp41 six-helix bundle for-
mation. In summary, the contact of HIV-1 IIIB and HIV-1
BaL, representatives of X4 and R5 viruses respectively,
with micronized CAP, resulted in a complex sequence of
events involving virus adsorption, exposure to low pH, in-
duction of gp41 six-helix bundles, and stripping off of vi-
ral envelopes and virus disintegration, ultimately
resulting in loss of infectivity.
In order to contribute to the understanding of the poten-
tial virucidal activity of anionic polymers, their capacity to
induce gp41 six-helix bundle formation was measured
and compared with that of CAP in soluble form (pH 7.0).
All polymers except Carbomer 974P elicited gp41 six-he-
lix bundle formation in HIV-1 IIIB, albeit in some cases
less efficiently in comparison with CAP (Fig. 4). On the
other hand, gp41 six-helix bundle formation in HIV-1 BaL
was detectable only for CAP and poly(naphthalene sul-
fonate) treated virus (Fig. 5) suggesting differences among
the anionic polymers with respect to their activity against
the R5 virus HIV-1 BaL. The induction of six-helix bundles
in HIV-1 does not seem to be the only mechanism in-
volved in virucidal activity of anionic polymers (compare
Figure 8
Inactivation of HIV-1 IIIB by polymeric anionic candidate
microbicides. HIV-1 IIIB (7 × 109 virus particles/100 µl) was
treated with the compounds indicated on the abscissa (final
concentrations 10 mg/ml except for Carbomer 974P [2.5 mg/
ml; neutralized to pH 7.0; at higher concentrations the solu-
tions became too viscous to handle]) for 5 min at 37°C. The
final dilution of BufferGel was 4-fold (final pH = 4.0). The
preparations were cooled on ice and virus particles were
separated from the polymers and their infectivity determined
as described in the Methods section. For comparison, results
obtained with a formulation of micronized CAP (= Aquateric;
see legend for Fig. 2) are shown.
Figure 9
Inactivation of HIV-1 BaL by polymeric anionic candidate
microbicides. HIV-1 BaL (2.5 × 109 virus particles/100 µl) was
treated as described in the legend for Fig. 8.
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Figure 10
Effect of polymeric anionic candidate microbicides on clotting
of ACD plasma. The compounds indicated on the abscissa
(final concentrations of 100 and 1000 µg/ml, respectively)
were added to fresh citrated plasma prewarmed to 37°C.
CaCl2 was added to a final concentration of 10 mM, and the
time when clot formation had started was measured. The
increase in clotting time as compared with the time required
for clotting of plasma in the absence of any added com-
pounds is shown.
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Fig. 5 with Figs. 8 and 9) and there might be other contrib-
uting processes.
Since CAP in micronized form was shown to cause disin-
tegration of HIV-1 virus particles [31], (Fig. 3), it was of in-
terest to determine whether any of the other anionic
polymeric microbicide candidates affect the integrity of vi-
rus particles. While HIV-1 IIIB was not affected significant-
ly by any of the polymers tested, CAP to some extent, but
surprisingly cellulose sulfate affected the integrity of HIV-
1 BaL particles (Fig. 6). These results were supported by
the observation that HIV-1 BaL gp120 after treatment with
cellulose sulfate, unlike virus associated gp120, did not
become precipitated with 3% PEG and failed to pellet by
centrifugation under conditions leading to sedimentation
of intact virus particles (Fig. 7)]. The differential sensitivity
of an R5 virus, HIV-1 BaL, as compared to an R4 virus,
HIV-1 IIIB, to the same negatively charged polyelectrolyte
appears unprecedented to the best of our knowledge.
Among the three polysaccharide sulfate esters (carrageen-
an, cellulose sulfate and dextran sulfate), cellulose sulfate
appeared to be more effective against HIV-1 BaL than the
other polymers. This might be due to the polysaccharide
backbone of cellulose [60] with a propensity to form
strong intermolecular hydrogen bonds and to be involved
in hydrophobic interactions more than soluble dextrans
[61] and galactose + 3,6-anhydrogalactose copolymers (=
the saccharide moiety of carrageenan) [62,63]. Among the
two polymers containing aryl sulfonates, poly(napthalene
sulfonate) was more effective than poly(styrene-4-sul-
fonate) with respect to induction of gp41 six-helix bun-
dles in HIV-1 BaL. This difference may possibly be due to
the high propensity of the uncharged part of the molecule
{poly(naphtalene)} to be involved in hydrophobic inter-
actions. Among the two carboxylate polymers (Carbomer
974P and CAP), only soluble CAP (at neutral pH) was
able to elicit the formation of gp41 six-helix bundles in
both HIV-1 IIIB and BaL and was virucidal against both of
these viruses. The insoluble, micronized form of CAP had
similar properties. The differences in biological activities
of these polymers is probably due to their noncharged
portions, i.e. mainly the occurrence of benzene rings in
CAP.
Polycarboxylates (soluble CAP and Carbomer 974P; Fig.
10) had a minimal effect on plasma coagulation. Among
the sulfonates and polysaccharide sulfates, carrageenan
and poly(napthalene sulfonate) had lower anti-coagulant
activity in comparison with cellulose sulfate, dextran sul-
fate and poly(styrene-4-sulfonate) (Fig. 10). Considera-
tion of these side effects might contribute to the process of
selection of preferred microbicides for future large-scale
use.
Conclusions
Among anionic polymers considered as topical microbi-
cides to prevent sexual transmission of HIV-1 {Carbomer
974P/BufferGel, carrageenan, CAP, cellulose sulfate, dex-
tran/dextrin sulfate, poly(napthalene sulfonate) and po-
ly(styrene-4-sulfonate)}, CAP formulated in a micronized
form, is the only compound which has a capacity to re-
move from physiological fluids infectious virus by adsorp-
tion onto the micronized particles. The interaction
between HIV-1 IIIB, a representative of X4 viruses, and
HIV-1 BaL, a representative of R5 viruses, with the micro-
nized form of CAP has the following consequences: 1)
elicitation of "dead-end" gp41 six-helix bundles expected
to render the virus incompetent to fuse with target cells; 2)
loss of virus integrity and stripping off of the envelope
glycoproteins; and 3) inactivation of virus infectivity. Elic-
itation of gp41 six-helix bundles and virucidal activity rep-
resent shared properties between micronized and soluble
(at sufficient concentrations) forms of CAP [37].
As determined by ELISA, the aforementioned polymers
other than CAP (except Carbomer 974P) also elicited
gp41 six-helix bundle formation in HIV-1 IIIB, albeit less
effectively than CAP. On the other hand, only poly(nap-
thalene sulfonate), in addition to CAP, elicited detectable
six-helix bundle formation in HIV-1 BaL. This suggests
that X4 and R5 viruses may be differently affected by some
of the polymeric compounds being considered as topical
microbicides. This was confirmed by the results of assays
for virucidal activity.
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